Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0781
    -0.0013 (-0.12%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • dólar/libra

    1.2626
    +0.0004 (+0.03%)
     
  • USD/JPY

    151.3490
    -0.0230 (-0.02%)
     
  • Bitcoin USD

    70,051.52
    -556.20 (-0.79%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Rexahn Pharmaceuticals (RNN) Jumps: Stock Rises 12.5% - Tale of the Tape

Rexahn Pharmaceuticals (RNN) was a big mover last session with its shares rising almost 13% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the uptrend of the company since Dec 31, as the stock is now up nearly 29%.

Over the last 30 days, this biopharmaceutical company did not witness any estimate revision and the Zacks Consensus Estimate also remained unchanged. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Rexahn Pharmaceuticals currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.

Another favorably ranked biomedical stock is AMAG Pharmaceuticals, Inc. (AMAG) with a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
REXAHN PHARMACT (RNN): Free Stock Analysis Report
 
AMAG PHARMA INC (AMAG): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Advertisement